0001193125-24-166938.txt : 20240624 0001193125-24-166938.hdr.sgml : 20240624 20240624160601 ACCESSION NUMBER: 0001193125-24-166938 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240619 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240624 DATE AS OF CHANGE: 20240624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 241064290 BUSINESS ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 8-K 1 d860451d8k.htm 8-K 8-K
false 0001880438 0001880438 2024-06-19 2024-06-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2024

 

 

AN2 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41331   82-0606654
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

1800 El Camino Real, Suite D  
Menlo Park, California   94027
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 331-9090

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.00001 par value   ANTX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 19, 2024, AN2 Therapeutics, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 23,360,239 shares of common stock of the Company, representing 78.31% of the 29,829,040 shares of common stock outstanding as of the close of business on April 23, 2024, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each matter.

 

  1.

To elect the nominees Margaret FitzPatrick, Patricia Martin and Melvin Spigelman, M.D. as Class II directors until the Company’s 2027 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows:

 

Name    Votes For      Votes
Withheld		      Broker
Non-Votes		  

Margaret FitzPatrick

      17,722,866        1,994,466        3,642,907  

Patricia Martin

      17,724,646        1,992,686        3,642,907  

Melvin Spigelman, M.D.

      17,755,144        1,962,188        3,642,907  

 

  2.

To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results were as follows:

 

Votes For

  

Votes Against

  

Abstentions

23,344,330   12,786   3,123

 

  3.

To approve the amendment and restatement of the Company’s certificate of incorporation to provide for exculpation of officers to the extent permitted by the General Corporation Law of the State of Delaware. The voting results were as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker Non-Votes

18,416,318   1,292,459   8,834   3,642,628

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
 No. 		    Description
3.1    Amended and Restated Certificate of Incorporation of AN2 Therapeutics, Inc.
104    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AN2 Therapeutics, Inc.
Date: June 24, 2024     By:  

/s/ Joshua Eizen

      Joshua Eizen
      Chief Legal Officer
 EX-3.1 2 d860451dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

AN2 THERAPEUTICS, INC.

Eric Easom hereby certifies that:

ONE: The original name of this corporation is AN2 Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was February 24, 2017.

TWO: He is the duly elected and acting Chief Executive Officer of AN2 Therapeutics, Inc., a Delaware corporation.

THREE: The Certificate of Incorporation of this corporation is hereby amended and restated to read as follows:

I.

The name of this corporation is AN2 Therapeutics, Inc. (the “Company”).

II.

The address of the registered office of the Company is 850 New Burton Road, Suite 201, City of Dover, County of Kent, 19904 and the name of the registered agent of the Company at such address is Cogency Global Inc.

III.

The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware (“DGCL”).

IV.

A. This Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is 510,000,000 shares. 500,000,000 shares of which shall be Common Stock, having a par value per share of $0.00001. 10,000,000 shares of which shall be Preferred Stock, having a par value per share of $0.00001.

B. The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the “Board of Directors”) is hereby expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares for each such series and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding and not by more than the number of remaining authorized but undesignated shares of Preferred Stock. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock or any series thereof may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock.

C. Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Amended and Restated Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).

V.

For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:

A. MANAGEMENT OF BUSINESS. The management of the business and the conduct of the affairs of the Company shall be vested in its Board of Directors. The number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the Board of Directors.

B. BOARD OF DIRECTORS. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, upon the filing of this Amended and Restated Certificate of Incorporation, the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the Board of Directors, the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the term of office of the Class II directors shall expire and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.

Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

C. REMOVAL OF DIRECTORS.

1. Subject to the rights of any series of Preferred Stock to elect additional directors under specified circumstances or remove such directors elected by the holders of such series of Preferred Stock, neither the Board of Directors nor any individual director may be removed without cause.

2. Subject to any limitation imposed by applicable law and the rights of any series of Preferred Stock to remove directors elected by the holders of such series of Preferred Stock, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors.

D. VACANCIES. Subject to any limitations imposed by applicable law and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors or by the sole remaining director, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified or until such director’s earlier death, resignation or removal.

E. BYLAW AMENDMENTS.

1. The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Company. Any adoption, amendment or repeal of the Bylaws of the Company by the Board of Directors shall require the approval of a majority of the authorized number of directors. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Company; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Amended and Restated Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class.

2. The directors of the Company need not be elected by written ballot unless the Bylaws so provide.

3. No action shall be taken by the stockholders of the Company except at an annual or special meeting of stockholders called in accordance with the Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission.

4. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws of the Company.

5. In the event that a member of the Board of Directors of the Company who is not an employee of the Company, or any partner, member, director, stockholder, employee or agent of such member, other than someone who is an employee of the Company (collectively, the “Covered Persons”), acquires knowledge of any business opportunity matter, potential transaction, interest or other matter, unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in connection with such individual’s service as a member of the Board of Directors of the Company (a “Corporate Opportunity”), then the Company, pursuant to Section 122(17) of the DGCL and to the maximum extent permitted from time to time under Delaware law, (i) renounces any expectancy that such Covered Person offer an opportunity to participate in such Corporate Opportunity to the Company and (ii) to the fullest extent permitted by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by such Covered Person to the Company or any of its affiliates. No amendment or repeal of this paragraph shall apply to or have any effect on the liability or alleged liability of any officer, director or stockholder of the Company for or with respect to any opportunities of which such officer, director or stockholder becomes aware prior to such amendment or repeal.

VI.

A. The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law.

B. To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the

stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.

C. Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.

VII.

A. Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (A) any derivative claim or cause of action brought on behalf of the Company; (B) any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the Company, to the Company or the Company’s stockholders; (C) any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, arising out of or pursuant to any provision of the DGCL, this Amended and Restated Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Amended and Restated Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F) any claim or cause of action against the Company or any current or former director, officer or other employee of the Company, governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the “1933 Act”), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.

B. Unless the Company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act.

C. Any person or entity holding, owning or otherwise acquiring any interest in any security of the Company shall be deemed to have notice of and consented to the provisions of this Amended and Restated Certificate of Incorporation.

VIII.

A. The Company reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this Article VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation.

B. Notwithstanding any other provisions of this Amended and Restated Certificate of Incorporation or any provision of applicable law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the capital stock of the Company required by law or by this Amended and Restated Certificate of Incorporation or any certificate of designation filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all of the then outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII.

IX.

A. The liability of the officers of the Company for monetary damages shall be eliminated to the fullest extent under applicable law.

B. If applicable law is amended after approval by the stockholders of this Article IX to authorize corporate action further eliminating or limiting the personal liability of officers, then the liability of an officer to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.

C. Any repeal or modification of this Article IX shall only be prospective and shall not affect the rights or protections or increase the liability of any officer of the Company under this Article IX in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.

* * * *

FOUR: This Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors of the Company.

FIVE: This Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Sections 242 and 245 of the DGCL.

IN WITNESS WHEREOF, AN2 Therapeutics, Inc. has caused this Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 20th day of June, 2024.

 

AN2 THERAPEUTICS, INC.
By:  

/s/ Eric Easom

  Eric Easom
  Chief Executive Officer
 EX-101.SCH 3 antx-20240619.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 antx-20240619_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 antx-20240619_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 19, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001880438
Document Type 8-K
Document Period End Date Jun. 19, 2024
Entity Registrant Name AN2 THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-41331
Entity Tax Identification Number 82-0606654
Entity Address, Address Line One 1800 El Camino Real
Entity Address, Address Line Two Suite D
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94027
City Area Code (650)
Local Phone Number 331-9090
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value
Trading Symbol ANTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports antx-20240619.xsd antx-20240619_lab.xml antx-20240619_pre.xml d860451d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d860451d8k.htm": { "nsprefix": "antx", "nsuri": "http://www.an2therapeutics.com/20240619", "dts": { "schema": { "local": [ "antx-20240619.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "antx-20240619_lab.xml" ] }, "presentationLink": { "local": [ "antx-20240619_pre.xml" ] }, "inline": { "local": [ "d860451d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-19_to_2024-06-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d860451d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-19_to_2024-06-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d860451d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.an2therapeutics.com//20240619/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-166938-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-166938-xbrl.zip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d860451d8k_htm.xml IDEA: XBRL DOCUMENT 0001880438 2024-06-19 2024-06-19 false 0001880438 8-K 2024-06-19 AN2 THERAPEUTICS, INC. DE 001-41331 82-0606654 1800 El Camino Real Suite D Menlo Park CA 94027 (650) 331-9090 false false false false Common Stock, $0.00001 par value ANTX NASDAQ true false